Seizure: An Adverse Effect of Regadenoson in Myocardial Perfusion Imaging
Regadenoson is a selective adenosine 2a (A2a) receptor agonist that is used in cardiac stress testing to evaluate for ischemic heart disease and has largely replaced adenosine in the modern era. Since adenosine receptors are involved in synaptic transmission between neurons throughout the central ne...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2019/6240605 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849308546820210688 |
|---|---|
| author | Sohab S. Radwan Owen G. Schwartz |
| author_facet | Sohab S. Radwan Owen G. Schwartz |
| author_sort | Sohab S. Radwan |
| collection | DOAJ |
| description | Regadenoson is a selective adenosine 2a (A2a) receptor agonist that is used in cardiac stress testing to evaluate for ischemic heart disease and has largely replaced adenosine in the modern era. Since adenosine receptors are involved in synaptic transmission between neurons throughout the central nervous system (CNS) including the cerebral cortex, hippocampus, and other structures as well, regadenoson can lower the seizure threshold in susceptible individuals. Epileptogenic activity is an uncommon yet potentially severe adverse effect of regadenoson use, and therefore, more awareness is required in screening patients at risk and evaluating alternate ways to investigate coronary artery disease (CAD) in susceptible individuals. |
| format | Article |
| id | doaj-art-026144cae68942769d030d23e8515cd2 |
| institution | Kabale University |
| issn | 2090-6404 2090-6412 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Cardiology |
| spelling | doaj-art-026144cae68942769d030d23e8515cd22025-08-20T03:54:25ZengWileyCase Reports in Cardiology2090-64042090-64122019-01-01201910.1155/2019/62406056240605Seizure: An Adverse Effect of Regadenoson in Myocardial Perfusion ImagingSohab S. Radwan0Owen G. Schwartz1Department of Internal Medicine, MedStar Washington Hospital Center, USADepartment of Internal Medicine, MedStar Washington Hospital Center, USARegadenoson is a selective adenosine 2a (A2a) receptor agonist that is used in cardiac stress testing to evaluate for ischemic heart disease and has largely replaced adenosine in the modern era. Since adenosine receptors are involved in synaptic transmission between neurons throughout the central nervous system (CNS) including the cerebral cortex, hippocampus, and other structures as well, regadenoson can lower the seizure threshold in susceptible individuals. Epileptogenic activity is an uncommon yet potentially severe adverse effect of regadenoson use, and therefore, more awareness is required in screening patients at risk and evaluating alternate ways to investigate coronary artery disease (CAD) in susceptible individuals.http://dx.doi.org/10.1155/2019/6240605 |
| spellingShingle | Sohab S. Radwan Owen G. Schwartz Seizure: An Adverse Effect of Regadenoson in Myocardial Perfusion Imaging Case Reports in Cardiology |
| title | Seizure: An Adverse Effect of Regadenoson in Myocardial Perfusion Imaging |
| title_full | Seizure: An Adverse Effect of Regadenoson in Myocardial Perfusion Imaging |
| title_fullStr | Seizure: An Adverse Effect of Regadenoson in Myocardial Perfusion Imaging |
| title_full_unstemmed | Seizure: An Adverse Effect of Regadenoson in Myocardial Perfusion Imaging |
| title_short | Seizure: An Adverse Effect of Regadenoson in Myocardial Perfusion Imaging |
| title_sort | seizure an adverse effect of regadenoson in myocardial perfusion imaging |
| url | http://dx.doi.org/10.1155/2019/6240605 |
| work_keys_str_mv | AT sohabsradwan seizureanadverseeffectofregadenosoninmyocardialperfusionimaging AT owengschwartz seizureanadverseeffectofregadenosoninmyocardialperfusionimaging |